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Before the first Haemophilus influenzae type
b (Hib) polysaccharide vaccine was introduced in
1985, Hib was the most common cause of
bacterial meningitis in children under 5 years of
age (approximately 12,000 cases per year, most in
children younger than 18 months [1]); approxi-
mately 5% of affected children died. Neurologic
sequelae developed in 15% to 30% of the
surviving children (1). An additional estimated
7,500 cases of other invasive Hib infections also
occurred annually in young children (1). The
cumulative risk for Hib invasive disease before
the age of 5 was one in 200 children, similar to the
risk for poliomyelitis during the 1950s (1,2).
The incidence of Hib invasive disease among
children aged 4 years or younger has declined by
98% since the introduction of Hib conjugate
vaccines, initially licensed in 1989 for use in
children aged 15 months or older, then for infants
beginning at 2 months of age in 1990 (3-6). One goal
of the Childhood Immunization Initiative (7) was to
eliminate invasive Hib disease among children aged 4
years or younger by 1996; however, approximately
300 cases of H. influenzae (Hi) invasive disease per
year continue to be reported (3).
Moreover, Hi invasive disease is an impor-
tant cause of illness and death in
immunocompromised persons and adults with
certain underlying medical conditions (8-11). The
average incidence of Hi invasive disease from 1988
to 1990 was estimated at 1.7 cases per 100,000; 50%
of cases examined in this study were due to Hib (8).
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We analyzed national Haemophilus influenzae (Hi) surveillance data from 1994
and 1995 to describe the epidemiology of Hi invasive disease among persons of all
ages. Serotype data were available for 376 (56%) of 669 reported Hi cases among
children aged 4 years or younger; 184 (49%) were H. influenzae type b (Hib). Among
children aged 4 or younger, incidence (per 100,000) of all Hi invasive disease was 1.8
in 1994 and 1.6 (p < 0.05) in 1995. Children aged 5 months or younger had the highest
average annual incidence rate of Hib invasive disease (2.2 per 100,000); children aged
6 to 11 months had the next highest rate (1.2 per 100,000) (p < 0.05). Of 181 children with
Hib invasive disease whose age in months was known, 85 (47%) were too young (aged
5 months or younger) to have completed a primary series with an Hib-containing
vaccine. Of the 83 children with known vaccination status who were eligible to receive a
primary series (aged 6 months or older), 52 (63%) were undervaccinated, and the
remaining 31 (37%) had completed a primary series in which vaccine failed. Among
persons aged 5 years or older with Hi invasive disease, the lowest average annual
incidence was among those 20 to 39 years of age (0.15 per 100,000), and the highest
was among those aged 80 years or older (2.26 per 100,000). Among persons aged 5
years or older, serotype data were available for 1,372 (71%) of the 1,940 Hi invasive
disease cases; 159 (28%) of the 568 Hi cases with known serotype were due to Hib.230 Emerging Infectious Diseases Vol. 4, No. 2, April–June 1998
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Prior studies of Hi invasive disease among adults
found case-fatality rates of 26% to 36% (8-11).
In this article, we summarize the epidemi-
ology of Hi and Hib invasive disease among
children aged 4 years or younger and persons
aged 5 years or older in the United States
during 1994 and 1995.
Data Collection
We used three sources of surveillance data to
document the number of reported Hi invasive
disease cases with onset in 1994 and 1995. Cases
were reported to the Centers for Disease Control
and Prevention (CDC). Two sources were passive
surveillance systems: the National Notifiable
Diseases Surveillance System (NNDSS) and the
National Bacterial Meningitis and Bacteremia
Reporting System (NBMBRS); the third source was
the active, laboratory-based surveillance sites.
The NNDSS case reports of Hi invasive
disease are transmitted electronically from state
health departments to CDC as part of the weekly
notifiable disease reporting system. These
reports contain only demographic information.
Supplemental information, including Hi sero-
type, infection site, outcome, and Hib vaccination
status and specific vaccine received among
children aged 4 years or younger is transmitted
electronically or mailed to CDC on NBMBRS
reporting forms. During 1994, 10.5 million
persons were under active, laboratory-based
surveillance for Hi invasive disease: these
included residents of the state of Oklahoma;
three counties in the San Francisco Bay area of
California; eight counties in the metropolitan
area of Atlanta, Georgia; and four counties in
Tennessee (3). In 1995, 12.8 million persons were
under surveillance; an additional county in
Tennessee was added, and Maryland was included
in place of Oklahoma. Each site was contacted every
2 weeks to identify Hi invasive disease cases;
surveillance personnel then collected detailed data
on these cases. Data on cases from the active
surveillance sites were also mailed to CDC on a
form similar to the NBMBRS report form.
Information from the three data sources was
combined, and duplicates (cases with identical date
of birth, onset, county of residence, and demo-
graphic data) were eliminated. After the end of each
calendar year, each state health department was
contacted by telephone to send information on Hi
invasive disease cases among children aged 4
years or younger not previously reported to CDC
and to provide missing critical supplementary
information, such as vaccinations received.
Our analysis included confirmed and prob-
able cases. A confirmed case of Hi invasive
disease was defined as an illness clinically
compatible with invasive disease (such as
meningitis, pneumonia, cellulitis, epiglottitis,
peritonitis, pericarditis, septic arthritis, empy-
ema, and abscesses) with isolation of Hi from a
normally sterile site (e.g., cerebrospinal fluid or
blood). A probable case was defined as an illness
clinically compatible with detection of Hib
antigen in cerebrospinal fluid (12). Up to three
infection sites could be recorded from a list
including primary bacteremia, meningitis, pneu-
monia, cellulitis, epiglottitis, peritonitis, peri-
carditis, septic arthritis, or another specified site.
Completion of a primary vaccination series was
defined according to recommendations from the
Advisory Committee on Immunization Practices
(4). Hib vaccine doses administered fewer than 14
days before the onset of disease were excluded.
Data Analysis
U.S. census population estimates for 1994
and 1995 were used to calculate age- and race-
specific average annual incidence rates (calcu-
lated by [events/2] ÷ [population/2]) for all Hi
invasive disease and for documented Hib disease
(13). The difference between two rates was
regarded statistically significant at the 0.05 level
if it exceeded the following: 2 x (R12/N1 + R22/
N2)½ , where R1 is the rate corresponding to N1
events and R2 is the rate corresponding to N2
events (14). County average annual incidence
rates of Hi invasive disease were calculated by
using 1990 county population estimates and were
mapped with Atlas Mapmaker (15). For Hi invasive
disease cases among children aged 4 years or
younger, we looked at the proportion due to Hib, the
Hib vaccination history, and the age-specific and
geographic distribution of residual Hib cases. A chi-
square test of independence was used to test the
association between age category and outcome.
Findings
In 1994 and 1995, 1,277 and 1,332 cases of
invasive Hi disease were reported, respectively.
Although the overall incidence of invasive Hi
disease remained constant, the incidence of
invasive Hi disease among children aged 4 years
or younger was lower in 1995 (305 cases; 1.56 per
100,000) than in 1994 (364 cases; 1.84 per231 Vol. 4, No. 2, April–June 1998 Emerging Infectious Diseases
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100,000) (p < 0.05). During 1994 and 1995,
children 5 months or younger had the highest
reported disease incidence of Hi invasive disease
(8.02 per 100,000 children), Hib invasive disease
(2.20 per 100,000), and Hi invasive disease of
unknown serotype (3.57 per 100,000) (Table 1).
The incidence of Hi invasive disease, Hib invasive
disease, and Hi invasive disease of unknown
serotype was significantly greater (p < 0.05)
among children aged 5 months or younger than
among children 6 to 11 months of age, who had
the next highest rates; a high rate of Hi invasive
disease was also observed among adults aged 80
years or older. The lowest disease rates were
found in persons 5 to 19 and 20 to 39 years of age.
Hi isolates were serotyped for only 36% of
2,609 reported cases. A higher percentage of
isolates were serotyped among children aged 4
years or younger (56%) than among older persons
(29%) (Table 2). Among Hi cases in children aged
4 years or younger with reported serotype
information, Hib was the most common single
serotype (184 type b of 376 serotyped isolates);
Hib represented 49% of invasive disease and 65%
of meningitis. The average annual incidence for Hib
invasive disease was 0.47 per 100,000 children aged
4 years or younger. Among persons aged 5 years or
older, Hib accounted for 28% of serotyped isolates.
Among the 433 Hi case-patients younger
than 1 year of age for whom age in months was
reported during the study period, most (72%)
were aged 5 months or younger; 29% were
younger than 1 month of age (Figure 1).
Similarly, of 184 children aged 4 years or younger
with Hib invasive disease, most (133, 72%) cases
were in children younger than 1 year of age.
The highest average annual incidence rates
(5.1 per 100,000) of Hi invasive disease among
case-patients aged 4 years or younger were in
American Indians; comparisons with other race
or ethnic groups were statistically significant (p <
0.05) (Table 3). Similar race and ethnic
differences were noted for Hib invasive disease
incidence but not for Hi invasive disease of
unknown serotypes. Among case-patients aged 5
years or older, differences between race or ethnic
groups were less marked. The incidence rates
among male and female case-patients aged 5
years or older and among case-patients aged 4
years or younger were equivalent.
Infection site data were available for 1,556
(60%) case-patients (Table 4). Bacteremia was
the most frequently reported site of Hi invasive
disease for both children aged 4 years or younger
(62%) and persons aged 5 years or older (51%).
The second most frequently reported site of
Table 1. Number of cases and average annual incidence
rates of Hi and Hib invasive disease and Hi invasive
disease of unknown serotype, by age,a United States,
1994–1995
Hi serotype
Hi Hib unknown
Age group No.b Incid.c No.b Incid.c No.b Incid.c
0-5 mo 310 8.02 85 2.20 138 3.57
6-11 mo 123 3.18 45 1.16   45 0.16
1-4 yr 219 0.69 51 0.16   99 0.31
5-19 yr 179 0.16 23 0.02 108 0.10
20-39 yr 249 0.15 25 0.02 166 0.10
40-59 yr 405 0.33 42 0.03 280 0.23
60-79 yr 715 1.01 51 0.07 539 0.76
80 + yr 361 2.26 18 0.11 152 0.95
aDoes not include 31 cases missing age and 17 patients aged
<1 year but missing age in months.
bNumber of cases over the 2-year period.
cIncidence per 100,000 population.
Table 2. Serotype information for reported Hi invasive
disease  (n=2609) and meningitis cases (n=380),
stratified by age, United States, 1994–1995
No. (%) of children No. (%) of persons
aged 0–4 years aged ³ 5 years
Invasive Invasive
Serotype disease Meningitis disease Meningitis
Serotype b 184 (27) 101 (47)     159 (8)   41 (25)
Othera 114 (17)   39 (18)     171 (9)   26 (15)
Non-   78 (12)   16 (8)     238 (12)   25 (15)
  typeable
Unknown 293 (44)   57 (27) 1,372  (71)   75 (45)
Total 669 (100) 213 (100) 1,940  (100)167 (100)
aIncludes serotypes a, c, d, e, f.
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Figure 1.  Reported Hi invasive disease cases by age
and serotype, children aged <1 year,a United States,
1994–1995.
 aN=433; excluding 17 children aged <1 year missing age in
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invasive disease among children aged 4 years or
younger was meningitis (44%), and among persons
aged 5 years or older it was pneumonia (36%).
Outcome data were available for 1,380 (53%)
of 2,609 case-patients with Hi invasive disease.
Among case-patients with known outcome, the
overall case-fatality ratio (CFR) was 14%. The
CFR differed by age; the CFRs among case-
patients aged 0 to 1 year, 1 to 29 years, 30 to 59
years, and 60 years of age or older were 10%, 6%,
13%, and 24%, respectively (p < 0.001).
During 1994 and 1995, a moderate seasonal
pattern of Hi and Hib invasive disease was
observed, with more cases occurring during the
winter months (Figure 2); this pattern was
similar for children 4 years of age or younger
(data not shown).
To determine the remaining cases of Hib
invasive disease, data on the number of Hib
vaccine doses received were reviewed for the 184
reported cases among children aged 4 years or
younger by the age (in months) of the case-patient
(Table 5). Eighty-five (47%) of the 181 children
aged 4 years or younger with known age in
months were too young (5 months or younger) to
have completed a primary series with the most
commonly used Hib vaccines (three-dose primary
series). Of the 149 children aged 4 years or
younger with known vaccination status, 83 were
eligible (aged 6 months or older) to receive a
primary series; of these, 52 (63%) were
undervaccinated. Thirty-one (37%) of the 83
children had completed a primary series with
either three doses of HbOC (Wyeth-Lederle
Laboratories, Pearl River, NY) or PRP-T (Pasteur
Mérieux Connaught, Lyon, France), or with two
doses of PRP-OMP (Merck, Inc., West Point, PA),
or one dose with any Hib-containing vaccine on or
after 15 months of age.  Manufacturer and
vaccine lot information was available for 22 of the
Table 3. Number of cases and average annual incidence rates of Hi and Hib invasive disease and Hi invasive disease
of unknown serotype, by race and ethnicity,a United States, 1994–1995
Children aged 0–4 years Persons aged ³5 years
Hi: unknown
All Hi Hib serotypes All Hi
Race/ethnicity No.b Incidencec No.b Incidencec No.b Incidencec No.b Incidencec
Non-Hispanic
White 338 1.34 102 0.40 150 0.59 1,269 0.35
Black 122 2.08   32 0.55   52 0.89    258 0.45
American Indian   18 5.10   10 2.83     3 0.84      12 0.37
Asian or Pacific Islander   13 0.86     3 0.20     6 0.40      21 0.13
Hispanic   94 1.49     7 0.11   31 0.49      70 0.15
aDoes not include 84 (13%) of children aged  £ 4 years,  and 310 (16%) of persons aged  ³ 5 years for whom race and ethnicity data
were missing.
bNumber of cases over the 2-year period.
cPer 100,000 population.
Table 4.  Reported infection sitea among Hi invasive
disease cases,b United States, 1994–1995
Number (%)
Children aged Persons aged
Site 0-4yearsc ³5  yearsd
Bacteremiae 299 (62) 551 (51)
Meningitis 213 (44) 167 (16)
Pneumonia   42 (9) 390 (36)
Cellulitis   19 (4)     7 (1)
Epiglottitis     8 (2)   19 ( 2)
aIncludes case-patients with multiple infection sites, such as
meningitis and bacteremia.
bCase-patients with known infection site (n=1,556).
cN=485.
dN=1,071.
eBacteremia is reported following positive blood culture
results, with or without foci.
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Figure 2.  Reported Hi invasive disease cases by
serotype and month of onset,a United States, 1994–
1995.
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31 children who had received a primary series.
No single lot predominated, and no child received
vaccine from the same lot for all doses.
Overall, 49 states and 673 (21%) of the 3,137
U.S. counties reported at least one Hi invasive
disease case with disease onset during the 2-year
period; of these, 327 (49%) counties (from 47
states) reported two or more Hi cases (Figure 3A).
Forty-seven states and 339 (11%) of counties
reported Hi invasive disease cases among
children aged 4 years or younger, and 42 states
and 137 (4%) counties reported Hib cases during
the 2-year period; 25 (18%) of these counties
reported two or more Hib cases (range 2 to 8
cases). In these 25 counties, the incidence for Hib
invasive disease was 0.41 to 12.19 per 100,000
children aged 4 years or younger (Figure 3B).
Among the 14 counties with two Hib cases, the
median time between cases was 139 days (range
14 to 334 days). In three of the 11 counties with
three or more Hib invasive disease cases, children
were too young (aged 5 months or younger) to have
completed a primary series with an Hib vaccine; in
the remaining eight counties, 20 (67%) of 30
children had been eligible for vaccination (aged 6
months or older) and only one child had completed
a primary series. In these 11 counties, the incidence
for Hib invasive disease was 0.41 to 4.31 per 100,000
children aged 4 years or younger.
Conclusions
Invasive Hib disease among children aged 4
years or younger in the United States has become
rare because of the introduction and widespread
use of conjugate Hib vaccines. Although national
vaccination coverage of children 19 to 35 months
of age with three or more doses of Hib conjugate
vaccines only reached 90% in 1995 and some
metropolitan areas had lower coverage rates
(16,17), all Hi invasive disease incidence in 1994
and 1995 was 98% lower than during the
prevaccine era. During that era, Hib invasive
disease was the cause of more than 95% of Hi
invasive disease (18-22). While our results were
not directly comparable to prevaccine Hib
invasive disease estimates because of reliance on
passive reporting and lack of serotype data (23),
in the active surveillance sites, the race-adjusted
Table 5. Children aged £4 years with invasive Hib
disease,a by number of Hib vaccine doses received and
age group, United States, 1994–1995
No. of children Vaccination
Age  receiving vaccineb status
(mos.) Rec.c 0 1234unknown Total
0-1 0 15   2   17
2-3 1 17 12   9   38
4-5 2   7 13   2   8   30
6-11 3 13   8 11   6   7   45
12-18 4   5   1   2   7 2   0   17
19-59 4 11   5   1   7 4   6   34
Total 4 68 39 16 20 6 32 181
aExcludes three children aged <1 year but missing age in
months; vaccination status was unknown for two of the
children, and one child was unvaccinated.
bFive children completed a primary series with 2 doses of
PedvaxHIB (at ages 7, 11, 13, 14, and 43 months); two
children completed a primary series with 1 dose at  ³ 15
months of age.
cCumulative recommended  doses for PRP-T and HbOC
vaccines.
Figure 3. A. Average annual incidence of Hi invasive
disease among persons of all ages, by county, United
States, 1994–1995. B.  Reported number of Hib
invasive disease cases among children aged  £ 4 years,
by county, United States, 1994–1995.
> 2.06 1.07 - 2.05 0.51 - 1.06 0.01 - 0.50
A
1 case > 2 cases
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incidence of Hib invasive disease declined 99%
from 1989 to 1995 (3). Before Hib conjugate
vaccine availability in 1988, the highest Hib
invasive disease incidence had been in children 6
to 17 months of age (estimated annual incidence
of 275 and 223 per 100,000 for children 6 to 11 and
12 to 17 months of age, respectively), compared
with children 5 months of age or younger
(estimated annual incidence of 148 per 100,000)
(18-22). However, during 1994 and 1995, children
aged 5 months or younger had the highest
incidence of Hib invasive disease of all age groups
(2.2 per 100,000) (Table 1); these children were
too young to have completed a primary
vaccination series.
Consistent with previous studies of Hib
invasive disease in children aged 4 years or
younger in the prevaccine era, we found higher
Hi and Hib disease incidence among American
Indian (the highest incidence rates), black, and
Hispanic children than among Asian or Pacific
islander and white children (18,20). In the
prevaccine era, Hib invasive disease rates among
American Indian children were approximately
five times higher than among non-American
Indian children in Alaska (annual incidence of
601 per 100,000 children) (20). Although
important progress has been made in reducing
Hib invasive disease in this population, American
Indian children continue to have higher disease
incidence than other racial or ethnic groups. The
reasons for the higher Hib invasive disease
incidence among some ethnic or racial groups or
some regions are unknown but could be
associated with one or more of the following: low
Hib vaccine coverage levels in an area (e.g., an
inner-city “pocket of need”), low socioeconomic
status, cofactors, host susceptibility, and high
levels of carriage in the population. In 1996, a
study of Alaskan native children aged 6 years or
younger with high vaccination coverage (>90%)
found a carriage level of 8%, a rate similar to that
in the prevaccine era (24). However, a 1992 study
in the Atlanta, Georgia, metropolitan area
documented a low (0.2%) carriage level among
children with a 75% Hib vaccination coverage
(25). In the United States, the reduction in the
number of reported cases has been greater than
expected when the efficacy of Hib conjugate
vaccines and the coverage of a primary series
alone are taken into account; this is likely due to
the reduction of pharyngeal carriage in vacci-
nated children, which protects nonvaccinated
persons in the community (i.e., herd immunity)
(18,26). High carriage levels are unlikely in most
areas of the United States; the difference in the
results of the two studies (24,25) may be due to the
use of different Hib conjugate vaccines, as well as to
different host and environmental factors. In
European countries that use Hib conjugate
vaccines, increasing vaccine use has been
associated with diminishing rates of both Hib
pharyngeal carriage and invasive Hib disease (26).
With the marked decline among children, the
occurrence of Hib invasive disease among older
persons (aged 5 years or older) has achieved
greater prominence. Although serotype data
were missing from most cases, reported cases
among both children (n = 184) and adults (n =
159) indicate persistent circulation of Hib.
Reported Hib invasive disease cases and
nasopharyngeal carriage among children have
decreased; however, because these data were
from passive reporting sources it is not clear if a
similar decrease in invasive Hib disease in older
children and adults has occurred nationally.
Because of underreporting of adult Hib invasive
disease cases nationally, 1994 to 1995 incidence
rates cannot be directly compared with rates
found in prior studies (8-11). In our study, 28% of
serotyped isolates were Hib; however, among
adults in the Atlanta, Georgia, metropolitan
active surveillance site, Hi invasive disease cases
due to Hib declined in 1990 to 1991 from 50% to
0% in 1995 to 1996 (8,27). Nevertheless, because
previous studies have found that most Hi and Hib
invasive disease occurred among
immunocompromised patients or patients with
underlying conditions (e.g., chronic lung disease,
splenectomy, leukemia, HIV infection, sickle-cell
disease), health-care providers should consider
Hib vaccination for patients at high risk (6).
Because of continued occurrence of Hib invasive
disease among older persons and infants too
young to be vaccinated, additional strategies may
be needed to eliminate Hib invasive disease
among children aged 4 years or younger. In
addition, ongoing surveillance for Hi invasive
disease is needed to monitor incidence among
older persons; case investigations may include
assessments for underlying immunosuppressive
conditions or ascertainment of other cofactors
such as prior or concomitant viral infections.
Continued decline in incidence of Hib
invasive disease in the United States requires
that children aged 4 years or younger be235 Vol. 4, No. 2, April–June 1998 Emerging Infectious Diseases
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appropriately vaccinated to protect them and
other children and infants in the community.
Intensive efforts to increase vaccination levels
among children in areas with coverage rates
lower than 90% are needed to reach the
elimination goal. Children should receive a
primary Hib vaccination series at ages 2, 4, and 6
months with either HbOC or PRP-T, or at ages 2
and 4 months with PRP-OMP (6). A booster dose
with any of the four licensed Hib conjugate
vaccines should be given at 12 to 15 months of age
(6). Among children who were eligible for
vaccination, timely completion of a primary
series might have prevented 63% of reported Hib
invasive disease cases in 1994 and 1995. Few (28)
Hib cases among children 4 years or younger
were reported in those who had completed a
primary series with Hib vaccine, which suggests
that vaccine failure was uncommon. However,
because of passive reporting, vaccination status
and vaccine failure may be underestimated. Hib
invasive disease in children too young to have
completed a primary series will continue to be a
barrier for elimination unless Hib nasopharyn-
geal carriage rates in the population (including
adults) approach zero.
Because the highest Hib invasive disease
incidence occurs among infants, all infants
should be appropriately vaccinated, beginning at
2 months of age. In a case-control study for
undervaccination among Hib invasive disease
cases among children aged 2 to 18 months in the
United States, risk factors for undervaccination
included low maternal education and having a
single mother (29); special outreach efforts may
be needed to vaccinate children at risk. Other
programmatic strategies to increase vaccination
rates include linkage of the Special Supplemental
Nutrition Program for Women, Infants and
Children (WIC) to vaccination assessment and
referral (30), implementation of immunization
registries and reminder/recall systems to encour-
age parents to vaccinate their children in a timely
fashion (28,31,32), and monitoring clinic cover-
age levels and providing feedback to clinic staff
(33). In addition to high vaccination coverage of
other children in the community to help reduce
carriage, breast-feeding of infants should be
promoted because it is protective against
invasive Hi disease in this age group (21). For
children aged 4 years or younger with Hib
invasive disease who have completed a primary
Hib vaccination series, case investigations may
include examining reasons for vaccine failure, such
as measuring antibodies to the polyribosylribitol
phosphate (PRP) capsule of Hib; undetectable
levels suggest lack of immune response (18).
To monitor the changing epidemiology of Hib
invasive disease and look for an increase or
decline in incidence among children and adults,
serotype information for all Hi invasive disease
cases is essential and will generate data needed to
examine new strategies for elimination. Surveil-
lance is necessary for detecting pockets of
continuing transmission and identifying areas in
need of improved vaccine coverage (3). Each case of
Hib invasive disease is a sentinel for circulation of
Hib in a community. In addition, Hib invasive
disease cases among children aged 4 years or
younger may be a marker for low community
coverage. Therefore, community immunization
policies, practices, and coverage levels should be
reviewed, and recommendations should be made, if
needed, to improve Hib vaccination coverage levels.
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